| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
Valproic acid (VPA) is widely used as an anticonvulsant drug. More recently, it has been reported that VPA improved the efficiency upon iPS reprogramming and the administration of VPA dramatically enhanced the restoration of hind limb function. The exact target molecules of the various effects of VPA remain unclear. We have developed a genetic approach using S pombe as a model organism. This study led to the following findings. We identified a novel VPA sensitive mutant of vas4-1/vrg4-v4, a mutant allele of the vrg4+ gene encoding S pombe homolog of Golgi GDP-mannose transmembrane transporter, and its mammalian homologue encodes disease responsible gene of cochlear like pelvic dysplasia. We found that Vrg4 localizes to Golgi, and isolated several genes as dosage-dependent suppressors of the VPA-sensitive phenotype of vrg4-v4 mutant. Furthermore we found the expression level of many genes was markedly increased or decreased upon VPA treatment using cap analysis of gene expression.
|
